CEREBAIN BIOTECH CORP. (CBBT) [Rocket]

Overview

CEREBAIN BIOTECH CORP. (CBBT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
09/03/2021	REVOKED	Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]:
01/27/2021	SC 13G/A	EMA Financial, LLC reports a 9.9% stake in CEREBAIN BIOTECH CORP
02/13/2020	SC 13G/A	EMA Financial, LLC reports a 9.9% stake in CEREBAIN BIOTECH CORP
10/01/2019	NT 10-K	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
07/23/2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/20/2019	10-Q	Quarterly Report for the period ended March 31, 2019
05/16/2019	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Jun-30-18	Jun-30-17	Jun-30-16	Jun-30-15	Jun-30-14	Jun-30-13	Jun-30-12	Nov-30-11
Revenues	-3.5	-14.0	0.1	0.1	2.4	-0.2	0.0	0.0
Revenue growth	-74.9%	-10562.3%	0.8%	-94.4%	-1361.5%
Cost of goods sold	0.0	0.0	0.7	-1.2	0.0	0.0	0.0	0.0
Gross profit	-3.5	-14.0	-0.6	1.3	2.4	-0.2	0.0	0.0
Gross margin	100.0%	100.0%	-421.5%	1002.1%	100.0%	100.0%
Selling, general and administrative	1.0	1.7		1.7	2.5	1.0	0.5
Sales and marketing	0.0	0.0	0.1	0.2	0.2	0.0
Research and development	0.3	0.2	0.2	0.4	0.3	0.1	0.0
General and administrative			1.5					0.0
EBIT	-4.9	-16.0	-2.4	-2.9	-3.4	-1.3	-0.9	0.0
EBIT margin	140.1%	114.5%	-1812.1%	-2207.9%	-142.3%	711.0%
Pre-tax income	-4.9	-16.0	-2.4	-2.9	-3.4	-1.3	-0.9	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-4.9	-16.0	-2.4	-2.9	-3.4	-1.3	-0.9	0.0
Net margin	140.2%	114.5%	-1813.9%	-2218.4%	-142.5%	711.0%

Diluted EPS	($0.58)	($2.13)	($0.41)	($0.65)	($0.93)	($0.43)	($0.03)	$0.00
Shares outstanding (diluted)	8.5	7.5	5.9	4.5	3.6	3.1	30.4	9.7

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.